Although we support the reissued “B” grade recommendation for screening for chlamydia and gonorrhea in all sexually active ages 24 and younger, we disagree that women ages 25 and over should only be screened if at high risk. We suggest that a “C” recommendation for men may capture that health care providers should assess patients’ risk factors and suggest screening accordingly.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Letter to California State Assembly Supporting Repeal of Sugary Drink Tax Preemption
March, 26, 2021: NCHR letter to California State Assembly supports the repeal of the sugary drink tax preemption to allow localities to implement life-saving taxes.
Read More »NCHR’s Comments to USPSTF on Aspirin to Prevent Morbidity and Mortality from Preeclampsia
March 22, 2021: We support this update, strengthened by new evidence, maintaining the 2014 “B” recommendation that there is moderate certainty of a substantial net benefit for the use of low-dose aspirin as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia.
Read More »NCHR’s Testimony to FDA Regarding Tanezumab for Osteoarthritis
March 24, 2021: We agree with the FDA’s assessment that the risk mitigation measures proposed for tanezumab are not likely to be feasible or effective, and there are serious risks, even after patients discontinue use.
Read More »NCHR Letter to Belvedere City Council Regarding Rubber Playground Surfaces
March 19, 2021: Dr. Diana Zuckerman’s letter to Belvedere City Council regarding the dangers of rubber playground surfaces to children and the community.
Read More »